Roots Analysis has just released the 2nd edition of their study on 'Cell and Gene Therapy CROs Market, 2021-2030'.
The development of cell and gene therapies is not only complex and challenging, but also subject to heavy regulatory scrutiny. Outsourcing is, therefore, a preferred operational model in this field, with innovator companies relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. Contract research organizations (CROs) that claim to have the necessary capabilities to facilitate cell and gene therapy-related R&D, usually have extensive experience and are well-aware of the nuances of ATMP design and development. Given the rising trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve/expand their respective offerings, they believe the cell and gene therapy CRO market is likely to evolve at a steady pace, till 2030.
Find more information, here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.